Despite a continuously increasing PSA level up to 4.0 ng/mL, the recurrence work-up with repeated whole-body contrast-enhanced [18F]PSMA-1007 PET/CT and cMRI scans at further follow-up in November 2023 did not show a malignant focus, but a moderately PSMA-avid, suprasellar residual meningioma with an SUVmax value of 8.4. This evidence concerns the gene FOLH1 and meningioma.